Back to top
more

Mylan N.V. (MYL)

(Delayed Data from NSDQ)

$28.01 USD

28.01
4,315,758

+0.33 (1.19%)

Updated May 3, 2019 04:00 PM ET

After-Market: $28.00 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Ekta Bagri headshot

Mylan Misses on Earnings and Sales in Q1

by Ekta Bagri

Mylan (MYL) missed on earnings and sales in the first quarter as challenges in North America persist.

    Why Is Mylan N.V. (MYL) Up 1.2% Since Its Last Earnings Report?

    by Zacks Equity Research

    Mylan N.V. (MYL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

      Should Value Investors Pick Mylan (MYL) Stock?

      by Zacks Equity Research

      Mylan (MYL) is an inspired choice for value investors, as it is hard to beat its incredible lineup of statistics on this front.

        Ryan McQueeney headshot

        Mylan (MYL) Posts Earnings Beat, In-Line Guidance

        by Ryan McQueeney

        Mylan N.V. (MYL) just released its latest quarterly financial results, posting adjusted earnings of $1.43 per share and revenues of $3.24 billion.

          Arpita Dutt headshot

          Will the Healthcare Landscape Change with the $69B CVS-Aetna Deal?

          by Arpita Dutt

          Will the $69 billion CVS Health (CVS)-Aetna acquisition trigger more such deals in the healthcare sector?

            Ekta Bagri headshot

            Mylan (MYL) Misses on Q3 Earnings & Sales

            by Ekta Bagri

            Mylan (MYL) missed on both sales and earnings in the third-quarter.

              Will Tinder & PMC Growth Aid Match Group (MTCH) Q3 Earnings?

              by Zacks Equity Research

              Match Group's (MTCH) third-quarter 2017 earnings results to benefit from steady market traction of apps like Tinder, which are driving higher PMC (paid-member count).

                Is a Surprise Coming for Mylan (MYL) This Earnings Season?

                by Zacks Equity Research

                Mylan (MYL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

                  Quanta Services (PWR) Poised to Beat Q3 Earnings: Here's Why

                  by Zacks Equity Research

                  Quanta Services' (PWR) third-quarter 2017 earnings results to benefit from thriving engineering & project management services, higher production of liquid fuels and the Stronghold acquisition.

                    High Collection Revenues to Aid Republic (RSG) Q3 Earnings?

                    by Zacks Equity Research

                    Focus on increasing operational efficiency and structural realignment of operations are likely to drive Republic Services' (RSG) Q3 earnings.

                      Voyager Therapeutics (VYGR) Jumps: Stock Rises 7.8%

                      by Zacks Equity Research

                      Voyager Therapeutics (VYGR) was a big mover last session, as the company saw its shares nearly 8% on the day amid huge volumes.

                        Tirthankar Chakraborty headshot

                        Company News For Oct 5, 2017

                        by Tirthankar Chakraborty

                        Companies in the news are: PEP,MAT,MYL,ODP

                          Mylan (MYL) Surges: Stock Moves 16.2% Higher

                          by Zacks Equity Research

                          Mylan N.V. (MYL) was a big mover last session, as the company saw its shares rise more than 16% on the day amid huge volumes.

                            Ryan McQueeney headshot

                            Teva Shares Plummet After Mylan's Copaxone Generic Gets FDA Approval

                            by Ryan McQueeney

                            Shares of Teva Pharmaceuticals (TEVA) opened more than 13% lower on Wednesday, plunging close to their 52-week low in the process. The struggling Israeli pharma firm, which has faced significant pressure to reduce its debt load, is sliding once again--this time because of a brand new competitor.

                              Implied Volatility Surging for Mylan (MYL) Stock Options

                              by Zacks Equity Research

                              Mylan (MYL) warrants investors' attention based on moves in the options market lately.

                                Benjamin Rains headshot

                                Why Did Mylan (MYL) Stock Surge Today?

                                by Benjamin Rains

                                Shares of much-maligned drugmaker Mylan NV (MYL) climbed on Thursday after the U.S. Justice Department announced that it officially reached a settlement with the company regarding its EpiPen lawsuit.

                                  Falling Earnings Estimates Signal Weakness Ahead for Mylan (MYL)

                                  by Zacks Equity Research

                                  Mylan (MYL) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.

                                    Ekta Bagri headshot

                                    Mylan (MYL) Misses on Q2 Earnings & Revenues

                                    by Ekta Bagri

                                    Mylan N.V. (MYL) reported disappointing results for the second quarter.

                                      Is a Surprise Coming for Mylan (MYL) This Earnings Season?

                                      by Zacks Equity Research

                                      Mylan (MYL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

                                        Is a Surprise in the Cards for Teva (TEVA) in Q2 Earnings?

                                        by Zacks Equity Research

                                        While the inclusion of sales from Actavis Generics acquisition may continue to pull up Teva Pharmaceutical Industries Ltd.'s (TEVA) sales, its generic segment may see weakness.

                                          Adamis Gets FDA Nod for Generic Version of Mylan's EpiPen

                                          by Zacks Equity Research

                                          Shares of Adamis Pharmaceuticals Corporation (ADMP) soared more than 50% after the FDA approved the company's Epinephrine injection, USP, (0.3 mg Pre-filled single dose syringe) which is the generic version of Mylan N.V.'s (MYL) EpiPen.

                                            Company News for May 11, 2017

                                            by Zacks Equity Research

                                            Companies in the News are: MYL,YELP,EA,WEN

                                              Ekta Bagri headshot

                                              Mylan (MYL) Tops on Q1 Earnings

                                              by Ekta Bagri

                                              Mylan (MYL) topped earnings in the first quarter.

                                                Swarup Gupta headshot

                                                Mylan vs. Teva: Which Is the Better Generics Stock Ahead of Earnings?

                                                by Swarup Gupta

                                                Mylan and Teva are scheduled to report on May 10 and May 11

                                                  Madeleine Johnson headshot

                                                  Mylan's EpiPen Recall Expanded to U.S.

                                                  by Madeleine Johnson

                                                  On Monday, Mylan NV???s (MYL) manufacturing partner Meridian Medical Technologies announced that it will expand its voluntary recall of the EpiPen to the United States after discussing with the Food and Drug Administration (FDA).